Funding announcement
QUE Oncology's non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer, published in The Lancet
QUE Oncology reports its non-hormonal drug Q-122 eased hot flushes in breast cancer patients on endocrine therapy, with Phase II results in The Lancet; the Emory–UniQuest venture is backed by Brandon BioCatalyst and Uniseed.